Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 6Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1Phase 1 1

Status

Recruiting 9Active not recruiting 6Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 5Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 3Prostate Adenocarcinoma 1Neoplasms 1Biochemically Recurrent Prostate Cancer 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × darolutamide × Clear all
NCT06120491 2026-05-27

EvoPAR-PR01

AstraZeneca

Phase 3 Active not recruiting
1,889 enrolled
Genitourinary

Prostatic Neoplasms

NCT05794906 2026-05-19

ARASTEP

Bayer

Phase 3 Active not recruiting
985 enrolled
Genitourinary

Biochemically Recurrent Prostate Cancer

NCT04136353 2026-05-06

DASL-HiCaP

University of Sydney

Phase 3 Active not recruiting
1,100 enrolled
Genitourinary

Prostatic Neoplasms

NCT04484818 2026-05-05

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
27 enrolled
Genitourinary

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT04464226 2026-04-15

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Bayer

Phase 3 Active not recruiting
402 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡